

Available at www.sciencedirect.com

SciVerse ScienceDirect

journal homepage: www.ejconline.com

Corrigendum

Corrigendum to “Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis” [Eur J Cancer 47 (12) (2011) 1826–1836]

Stephen J. Clarke ^{a,*}, Sonia Yip ^b, Chris Brown ^b, Guy A. van Hazel ^c, David T. Ransom ^d, David Goldstein ^e, G. Mark Jeffrey ^f, Niall C. Tebbutt ^g, Martin Buck ^h, Raymond M. Lowenthal ⁱ, Amy Boland ^b, Val Gebski ^b, John Zalcberg ^j, R. John Simes ^b, on behalf of the Australasian Gastro-Intestinal Trials Group

^a Department of Medicine, Concord Hospital, Concord, Sydney, Australia

^b National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, Australia

^c School of Medicine and Pharmacology, University of Western Australia, Perth, Australia

^d St. John of God Hospital, Perth, Australia

^e Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia

^f Oncology Service, Christchurch Hospital, Christchurch, New Zealand

^g Austin Health, Melbourne, Australia

^h Sir Charles Gairdner Hospital, Perth, Australia

ⁱ Royal Hobart Hospital and University of Tasmania, Hobart, Australia

^j Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

Please note that the title of this article was expanded incorrectly during editing but unfortunately this error was not picked up during proof correction.

The correct title is as follows:

Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis.

☆ DOI of original article: [10.1016/j.ejca.2011.04.024](https://doi.org/10.1016/j.ejca.2011.04.024)

* Corresponding author. Tel.: +61 297676587; fax: +61 297677603.

E-mail address: stephen.clarke@sydney.edu.au (S.J. Clarke).

0959-8049/\$ - see front matter © 2011 Elsevier Ltd. All rights reserved.

doi:[10.1016/j.ejca.2011.12.001](https://doi.org/10.1016/j.ejca.2011.12.001)